"Is it FDA-approved?" tends to come up almost immediately whenever someone hears about a new depression treatment. It is a good question. The trouble is that the answer is often more complicated than yes or no, and the complications matter a great deal if you are relying on commercial insurance to pay for care.
This explainer sorts out four terms you are likely to hear: FDA-approved, FDA-cleared, off-label, and compounded. It is written for people across the Midwest with insurance through an employer or the marketplace.
Why the question matters to so many people
Most of the 443 Midwest adults we surveyed expect FDA status to weigh on the choice. On how much it would count toward trying a new depression treatment, 40 percent answered a big factor, while 19 percent went further and called it the deciding one. Combined, that is 59 percent. For respondents on commercial plans, 173 of them, the combined share was 54 percent.
When those same respondents ranked what they want in a provider, FDA-approved treatment made the top two for 27 percent. Coverage outranked it by a wide margin, landing in the top two for 85 percent. Those two concerns are more connected than they look, and the terms below explain why.
FDA-approved
This term applies to drugs. It means the FDA reviewed evidence from clinical trials and concluded that the drug's benefits outweigh its risks for a specific use, in a specific population, at a specific dose. That use is spelled out on the drug's label.
Esketamine, sold as Spravato, is an example. Its FDA approval covers adult depression that standard treatment has left unrelieved. Its side effects put it under a restricted program as well: every dose happens inside a certified healthcare setting, and staff keep watch for two hours or longer afterward. Brain Recovery Centers has a plain guide to Spravato treatment for anyone who wants the details.
What it tends to mean for coverage: Commercial plans usually have a defined path for approved drugs used for their approved purpose. That path often includes prior authorization and documentation, but it exists.
FDA-cleared
This term generally applies to medical devices. Many devices reach the market through a process where the manufacturer shows the device is substantially equivalent to one already on the market. The FDA then clears it.
Transcranial magnetic stimulation, or TMS, is an example. TMS devices hold FDA clearance for adults living with major depression that antidepressants did not help enough. It is a legitimate, regulated treatment. It simply went through the device pathway rather than the drug pathway.
What it tends to mean for coverage: Many commercial plans cover TMS for depression with prior authorization, usually after several antidepressant trials. Do not dismiss a treatment because it is "only" cleared. For devices, that is the normal route.
Off-label
Off-label use means a doctor prescribes an FDA-approved drug for a purpose not listed on its label. This is legal and common across medicine. It is not automatically unsafe or improper. It just means nobody at the FDA has weighed the evidence for that specific purpose.
Ketamine given by IV infusion for depression is an example. Ketamine is FDA-approved as an anesthetic. Its use for depression is off-label.
What it tends to mean for coverage: Coverage for off-label uses is less predictable. IV ketamine given for depression is often excluded by commercial plans, leaving patients to pay themselves. Plans vary, so ask.
Compounded
A compounded drug is mixed by a pharmacy for an individual patient rather than manufactured as an approved product. Compounded drugs are not FDA-approved. The FDA does not review them for safety, effectiveness, or quality before they reach patients.
Many at-home ketamine products, such as lozenges or oral tablets, are compounded. The FDA has put out a public warning about compounded ketamine taken at home with no one monitoring.
What it tends to mean for coverage: These products are generally not covered by commercial plans for depression and are typically paid out of pocket.
Putting the four together
- Esketamine (Spravato): FDA-approved drug for treatment-resistant depression, supervised in a certified clinic.
- TMS: an FDA-cleared device, meant for depression that antidepressants left unresolved. No medication involved.
- IV ketamine: An approved drug, used off-label for depression.
- At-home compounded ketamine: Not FDA-approved for depression.
These are not interchangeable. Blurring them is one of the most common sources of confusion we see.
A note on marketing language
Clinic websites do not always use these terms precisely. You may see phrases like "FDA-approved medication" next to a service that is actually an off-label use of that medication, or a compounded product described in a way that suggests it went through FDA review. If the wording is vague, ask the clinic directly which of the four categories their treatment falls into, and ask them to put it in writing if you are paying out of pocket.
What FDA status cannot tell you
Regulatory status is a useful filter, but it has limits. Approval does not promise a treatment will work for you. Your particular history is a separate question that approval cannot answer. And a drug being approved does not mean every clinic offering it is a good one. Suitability is a question for a clinician.
Questions to bring to your doctor and your plan
- "Is this treatment approved or cleared for my condition, or would it be off-label?"
- "Do I meet the criteria my plan uses for this treatment?"
- "Is it billed under my medical benefit, my pharmacy benefit, or both?"
- "What will my share be for the whole course?"
Start with your doctor. Our survey put the doctor far in front, with 74 percent saying their own physician's recommendation would move them to give a new treatment a chance. Your doctor can also tell you which of these four categories a treatment falls into, which is often the first thing your insurer will want to know.
This explainer is general information and not medical or legal advice.
When depression pushes your thoughts toward ending your life, do not sort out approval categories first. Call or text 988 now; a trained Suicide and Crisis Lifeline counselor picks up around the clock, at no cost.
Methodology
Our numbers trace to one Pollfish consumer panel survey. By June 23, 2026, when it closed, 443 people had completed it, all between 18 and 64, from Indiana, Wisconsin, Oklahoma, Minnesota, Nebraska, Kansas, Missouri, Illinois, Ohio, and Iowa. Pollfish has validated the panel, and apart from the commercial plan group every figure describes the full sample. Our publisher ordered this FDA-status research and footed the bill.